Inhibikase Therapeutics, Inc. (IKT): R&D Expense
$29.79M
Year ended 2025-12-31
$38.24M
Trailing 12 months to 2026-06-30
+35.3%
3-year compound annual growth
+101.6%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $29.79M | +73.1% | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | $17.21M | +26.4% | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | $13.62M | +13.2% | 2025-03-27, From 2023-01-01 |
| 2022-12-31 | $12.03M | +6.0% | 2024-03-27, From 2022-01-01 |
| 2021-12-31 | $11.36M | n/m | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $893.8K | n/a | 2022-03-31, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | 2025-12-31 | $29.79M | +73.1% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $201.58M | +171.6% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $89.95M | -54.9% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $109.44M | -15.9% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $166.42M | -34.0% |
| SAB Biotherapeutics, Inc. (SABS) | 2025-12-31 | $34.35M | +13.6% |
| Neumora Therapeutics, Inc. (NMRA) | 2025-12-31 | $176.06M | -12.4% |
| Aura Biosciences, Inc. (AURA) | 2025-12-31 | $90.30M | +23.2% |
| Cabaletta Bio, Inc. (CABA) | 2025-12-31 | $142.67M | +46.8% |
Compare IKT, VXRT, EDIT, CRBU side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗